【制药网 行业动态】在肿瘤免疫治疗领域,CD47 靶点曾如一颗璀璨的明星,闪耀着希望的光芒,被寄予厚望成为攻克癌症的有力武器。然而,近年来,围绕这一靶点的研发之路却布满荆棘,众多药企接连折戟,让 CD47 靶点的前景蒙上了一层厚重的阴霾。CD47作为一种广泛表达于多种癌细胞表面的跨膜糖蛋白,尤其是在血液肿瘤中呈现高表达状态,其 “致癌机制” 较为明确。一方面,它与巨噬细胞表面的信号调节蛋白 α(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.